Xeme Biopharma, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2005-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.xemebiopharma.com
Clinical Trials
2
Active:0
Completed:0
Trial Phases
2 Phases
Phase 1:1
Phase 2:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 1
1 (50.0%)Phase 2
1 (50.0%)Oncoquest-L Vaccine in Patients With Previously Untreated Stage III or IV, Asymptomatic, Non-bulky Follicular Lymphoma
Phase 2
Not yet recruiting
- Conditions
- Follicular Lymphoma
- First Posted Date
- 2014-07-18
- Last Posted Date
- 2021-04-08
- Lead Sponsor
- XEME Biopharma Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT02194751
- Locations
- 🇺🇸
Southeastern Regional Medical Center at CTCA, Newnan, Georgia, United States
Vaccine Therapy for Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL)
Phase 1
- Conditions
- Chronic Lymphocytic Leukemia (CLL)
- First Posted Date
- 2013-11-05
- Last Posted Date
- 2021-04-08
- Lead Sponsor
- XEME Biopharma Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT01976520
- Locations
- 🇺🇸
Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago, Illinois, United States
News
No news found